Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Gastric/GEJ Cancer
What factors (age, PS) do you consider to avoid using FLOT in the perioperative treatment of gastric and esophageal cancers?
Related Questions
Would you offer zolbetuximab + chemotherapy in a presumed metastatic duodenal bulb adenocarcinoma with 80% Claudin18.2 expression?
How would you treat newly diagnosed stage IV GEJ adenocarcinoma with both Claudin 18.2 and HER2 (3+ via IHC) overexpression?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
How are you sequencing immunotherapy with zolbetuximab in locally advanced/metastatic GEJ cancer when CPS >5 and Claudin 18.2+ (>75%)?
How would you manage a solitary unresectable liver metastasis?
Would you offer adjuvant therapy for resected GB cancer > 6 months of surgery time if there are high risk features (pT3N0, positive margins, + PNI) and therapy was delayed due to hepatic abscess post operative?
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
Is there a role for chemotherapy for asymptomatic Well-Differentiated Papillary Mesothelioma or Multicystic mesothelioma?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
